Influence of an intravenous dose of aurothiomalate on the status of low-molecular-mass endogenous metabolites in blood plasma: a proton nuclear magnetic resonance (NMR) study

Martin Grootveld; Andrew Claxson; Declan Naughton; Michael Whelan; Alexandra Furst; David Blake

Influence of an intravenous dose of aurothiomalate on the status of low-molecular-mass endogenous metabolites in blood plasma: a proton nuclear magnetic resonance (NMR) study

Martin Grootveld
, Andrew Claxson
, Declan Naughton
, Michael Whelan
, Alexandra Furst
, David Blake

Research output: Contribution to journal › Article › peer-review

Abstract

The effect of aurothiomalate on the status of a wide range of low-molecular-mass endogenous metabolites in blood plasma obtained from animals treated with an intravenous dose of this second-line agent (150 mg/kg) has been assessed by high field proton Hahn spin-echo NMR spectroscopy. As well as modulating the effective concentrations of NMR-detectable biomolecules, aurothiomalate induces a time-dependent decrease in plasma levels of triacylglycerols with a corresponding elevation in the concentration of the ketone body 3-D-hydroxybutyrate, indicating an increased utilisation of fats for energy in rats treated with this 1:1 gold(I)-thiolate complex. These observations may reflect the toxic side-effects that are associated with aurothiomalate treatment.

Original language	English
Pages (from-to)	65-69
Journal	Agents and Actions Supplements
Volume	32
Publication status	Published - 1991

Keywords

Allied health professions and studies

Access to Document

http://www.ncbi.nlm.nih.gov/pubmed/1906237

Cite this

@article{355c78ed9c4547258052c7ff4c653bc3,

title = "Influence of an intravenous dose of aurothiomalate on the status of low-molecular-mass endogenous metabolites in blood plasma: a proton nuclear magnetic resonance (NMR) study",

abstract = "The effect of aurothiomalate on the status of a wide range of low-molecular-mass endogenous metabolites in blood plasma obtained from animals treated with an intravenous dose of this second-line agent (150 mg/kg) has been assessed by high field proton Hahn spin-echo NMR spectroscopy. As well as modulating the effective concentrations of NMR-detectable biomolecules, aurothiomalate induces a time-dependent decrease in plasma levels of triacylglycerols with a corresponding elevation in the concentration of the ketone body 3-D-hydroxybutyrate, indicating an increased utilisation of fats for energy in rats treated with this 1:1 gold(I)-thiolate complex. These observations may reflect the toxic side-effects that are associated with aurothiomalate treatment.",

keywords = "Allied health professions and studies",

author = "Martin Grootveld and Andrew Claxson and Declan Naughton and Michael Whelan and Alexandra Furst and David Blake",

year = "1991",

language = "English",

volume = "32",

pages = "65--69",

journal = "Agents and Actions Supplements",

issn = "0379-0363",

}

TY - JOUR

T1 - Influence of an intravenous dose of aurothiomalate on the status of low-molecular-mass endogenous metabolites in blood plasma

T2 - a proton nuclear magnetic resonance (NMR) study

AU - Grootveld, Martin

AU - Claxson, Andrew

AU - Naughton, Declan

AU - Whelan, Michael

AU - Furst, Alexandra

AU - Blake, David

PY - 1991

Y1 - 1991

N2 - The effect of aurothiomalate on the status of a wide range of low-molecular-mass endogenous metabolites in blood plasma obtained from animals treated with an intravenous dose of this second-line agent (150 mg/kg) has been assessed by high field proton Hahn spin-echo NMR spectroscopy. As well as modulating the effective concentrations of NMR-detectable biomolecules, aurothiomalate induces a time-dependent decrease in plasma levels of triacylglycerols with a corresponding elevation in the concentration of the ketone body 3-D-hydroxybutyrate, indicating an increased utilisation of fats for energy in rats treated with this 1:1 gold(I)-thiolate complex. These observations may reflect the toxic side-effects that are associated with aurothiomalate treatment.

AB - The effect of aurothiomalate on the status of a wide range of low-molecular-mass endogenous metabolites in blood plasma obtained from animals treated with an intravenous dose of this second-line agent (150 mg/kg) has been assessed by high field proton Hahn spin-echo NMR spectroscopy. As well as modulating the effective concentrations of NMR-detectable biomolecules, aurothiomalate induces a time-dependent decrease in plasma levels of triacylglycerols with a corresponding elevation in the concentration of the ketone body 3-D-hydroxybutyrate, indicating an increased utilisation of fats for energy in rats treated with this 1:1 gold(I)-thiolate complex. These observations may reflect the toxic side-effects that are associated with aurothiomalate treatment.

KW - Allied health professions and studies

M3 - Article

C2 - 1906237

SN - 0379-0363

VL - 32

SP - 65

EP - 69

JO - Agents and Actions Supplements

JF - Agents and Actions Supplements

ER -

Influence of an intravenous dose of aurothiomalate on the status of low-molecular-mass endogenous metabolites in blood plasma: a proton nuclear magnetic resonance (NMR) study

Abstract

Keywords

Access to Document

Fingerprint

Cite this